Table 1.
Baseline characteristics of treated patients
| Suvorexant N = 142 | Placebo N = 143 | |
|---|---|---|
| Age | ||
| Mean (SD), years | 69.6 (8.7) | 69.1 (8.5) |
| <65 years, n (%) | 39 (27.5) | 44 (30.8) |
| ≥65 years, n (%) | 103 (72.5) | 99 (69.2) |
| Sex, n (%) | ||
| Women | 91 (64.1) | 95 (66.4) |
| Men | 51 (35.9) | 48 (33.6) |
| Body mass index | ||
| Mean (SD), kg/m2 | 27.1 (4.1) | 26.9 (3.7) |
| Underweight (<18.5), n (%) | 1 (0.7) | 0 (0) |
| Normal (18.5–24.9), n (%) | 44 (31.0) | 44 (30.8) |
| Overweight (25–30), n (%) | 68 (47.9) | 70 (49.0) |
| Obese (>30), n (%) | 29 (20.4) | 28 (19.6) |
| Race, n (%) | ||
| White | 86 (60.6) | 80 (55.9) |
| Black | 24 (16.9) | 22 (15.4) |
| Other | 32 (22.5) | 41 (28.7) |
| Ethnicity, n (%) | ||
| Hispanic/Latino | 89 (62.7) | 93 (65.0) |
| Non‐Hispanic/Latino | 52 (36.6) | 50 (35.0) |
| Geographical location, n (%) | ||
| North America | 96 (67.6) | 92 (64.3) |
| Europe | 16 (11.3) | 11 (7.7) |
| Other | 30 (21.1) | 40 (28.0) |
| MMSE | ||
| Mean (SD) | 22.5 (3.0) | 22.3 (3.3) |
| Mild (21–26), n (%) | 113 (79.6) | 113 (79.0) |
| Moderate (12–20), n (%) | 29 (20.4) | 30 (21.0) |
| APOE ε4 genotype, n (%) | ||
| Positive | 40 (28.2) | 53 (37.1) |
| Negative | 86 (60.6) | 74 (51.7) |
| Ambiguous | 3 (2.1) | 2 (1.4) |
| Missing | 13 (9.2) | 14 (9.8) |
| PSG measures, mean (SD) | ||
| AHI | 10.1 (8.2) | 8.8 (7.3) |
| PLMAI | 2.2 (4.4) | 2.1 (3.9) |
| Taking AD medication, n (%) | ||
| Donepezil | 47 (33.1) | 51 (35.7) |
| Memantine | 23 (16.2) | 19 (13.3) |
| Rivastigmine | 6 (4.2) | 4 (2.8) |
| Taking SSRI/SNRI, n (%) | ||
| Any | 23 (16.2) | 25 (17.5) |
Abbreviations: AD, Alzheimer's disease; AHI, Apnea/Hypopnea Index (number of apneas or hypopneas per hour assessed during PSG); APOE ε4, apolipoprotein ε4 gene variant; MMSE, Mini‐Mental State Exam; PLMAI, Periodic Leg Movement Arousal Index (number of leg movements associated with an arousal per hour assessed during PSG); PSG, polysomnography; SD, standard deviation; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin and norepinephrine reuptake inhibitor.